KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vir Biotechnology (VIR) Change in Receivables (2021 - 2024)

Historic Change in Receivables for Vir Biotechnology (VIR) over the last 4 years, with Q4 2024 value amounting to $8.7 million.

  • Vir Biotechnology's Change in Receivables rose 14256.79% to $8.7 million in Q4 2024 from the same period last year, while for Dec 2024 it was $6.5 million, marking a year-over-year increase of 105274.34%. This contributed to the annual value of $6.5 million for FY2024, which is 105274.34% up from last year.
  • According to the latest figures from Q4 2024, Vir Biotechnology's Change in Receivables is $8.7 million, which was up 14256.79% from $54000.0 recorded in Q3 2024.
  • Vir Biotechnology's Change in Receivables' 5-year high stood at $680.1 million during Q4 2021, with a 5-year trough of -$883.8 million in Q2 2022.
  • Moreover, its 4-year median value for Change in Receivables was $54000.0 (2024), whereas its average is $778384.6.
  • Examining YoY changes over the last 5 years, Vir Biotechnology's Change in Receivables showed a top increase of 14256.79% in 2024 and a maximum decrease of 18364.98% in 2024.
  • Vir Biotechnology's Change in Receivables (Quarter) stood at $680.1 million in 2021, then tumbled by 140.9% to -$278.2 million in 2022, then soared by 101.3% to $3.6 million in 2023, then surged by 142.57% to $8.7 million in 2024.
  • Its Change in Receivables stands at $8.7 million for Q4 2024, versus $54000.0 for Q3 2024 and -$2.7 million for Q2 2024.